Skip to main content

Southwell David P's Form 4 filing

Rocket Pharmaceuticals, Inc. (RCKT) · filed Apr 16, 2024

Accession no.
0001140361-24-020127
Filed
Apr 16, 2024
Trade date
Apr 12-15, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.95M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Southwell David PCIK 0001251553Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 12, 2024Common StockMOption exerciseAcquired+70,000$4.34+$303,800165,160Direct
Apr 12, 2024Common StockSSaleDisposed−59,716$24.22F2−$1,446,321.52105,444Direct
Apr 12, 2024Common StockSSaleDisposed−10,284$25.16F3−$258,745.4495,160Direct
Apr 15, 2024Common StockMOption exerciseAcquired+29,624$4.34+$128,568.16124,784Direct
Apr 15, 2024Common StockSSaleDisposed−10,000$24.05F5−$240,500114,784Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 12, 2024Common StockMOption exerciseDisposed−70,000$4.34−$303,80029,624Direct
Apr 15, 2024Common StockMOption exerciseDisposed−29,624$4.34−$128,568.160Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.87 to $24.68. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F3

Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.155 to $25.17. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F5

Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.85 to $24.335. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)